Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | WEE1 | P30291 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382594 | 0.83 | GAA (0.58) | NQO1MAOAGAAMAOBMGAM | |
| SCHEMBL5413220 | 0.79 | CDK4 (0.49) | NQO1MAOAGAAMAOBMGAM | |
| SCHEMBL22875997 | 0.78 | PDE3B (0.58) | PDE3BPDE3AMAOAGAAMEN1 | |
| SCHEMBL3298558 | 0.77 | PDE5A (0.43) | NQO1PDE3BPDE3AMAOAGAA | |
| SCHEMBL13412897 | 0.76 | PDE3B (0.56) | PDE3BPDE3AMAOAGAAMEN1 | |
| SCHEMBL384204 | 0.76 | EGFR (0.48) | MEN1KMT2AEGFRSRCGRIN2D | |
| SCHEMBL28065372 | 0.76 | EGFR (0.48) | GAAMEN1KMT2APOLBCASP6 | |
| SCHEMBL21563925 | 0.75 | PDE3B (0.55) | NQO1PDE3BPDE3AGAAMEN1 | |
| SCHEMBL3874953 | 0.72 | IMPDH2 (0.63) | NQO1GAAMEN1KMT2APOLB | |
| SCHEMBL30873777 | 0.72 | IMPDH2 (0.63) | NQO1GAAMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056929-B2 | Benzo[b]pyrano[3,2-h]acridin-7-one compounds | LES LABORATOIRES SERVIER (FR) | 2006-06-06 | — | — | US | disclosed |
| US-20040063702-A1 | Benzo[b]pyrano[3,2-h]acridin-7-one compounds | LES LABORATOIRES SERVIER (FR) | 2004-04-01 | — | — | US | disclosed |
| US-6642248-B2 | Antitumor, anticancer agent | LES LABORATORIES SERVIER (FR) | 2003-11-04 | — | — | US | disclosed |
| US-20030073841-A1 | New benzo [b] pyrano [3,2-h] acridin-7-one compounds | LES LABORATOIRES SERVIER (FR) | 2003-04-17 | — | — | US | disclosed |
| EP-1297835-A1 | Benzo[b]pyrano[3,2-h]acridin-7-one derivatives, processes for their preparation and pharmaceutical compositions thereof | LES LABORATOIRES SERVIER (FR) | 2003-04-02 | — | — | EP | disclosed |
| US-6503919-B1 | Anticarcinogenic agents | LES LABORATOIRES SERVER (FR) | 2003-01-07 | — | — | US | disclosed |
| EP-1042326-B1 | NOVEL ACRONYCINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS | SERVIER LAB (FR) | 2002-06-19 | — | — | EP | disclosed |
| EP-1061081-B1 | 7-Oxo-2,3,7,14-tetrahydro-1H-benzo[b]pyrano[3,2-h]acridine carboxylate derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-04-17 | — | — | EP | disclosed |
| US-6288073-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS | ADIR ET COMPAGNIE (FR) | 2001-09-11 | — | — | US | disclosed |
| EP-1061081-A1 | 7-Oxo-2,3,7,14-tetrahydro-1H-benzo[b]pyrano[3,2-h]acridine carboxylate derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2000-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063702-A1 | Benzo[b]pyrano[3,2-h]acridin-7-one compounds | OXGR1, OXER1, CBR1 | NQO1 875/4885PDE3B 4462/4885PDE3A 3974/4885 |
| US-20030073841-A1 | New benzo [b] pyrano [3,2-h] acridin-7-one compounds | OXGR1, OXER1, NAT1 | NQO1 574/4885PDE3B 4345/4885PDE3A 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.